HER2CLIMB brain metastases analysis: intracranial efficacy and survival with tucatinib
Among the HER2CLIMB patients with brain metastases, tucatinib doubled the intracranial response rate, cut the risk of intracranial progression or death by about two thirds and lengthened survival.
Overview
Exploratory analysis of the 291 HER2CLIMB patients with brain metastases at baseline, including 174 with active lesions.
Risk of intracranial progression or death was reduced by 68 percent with tucatinib, median central nervous system progression-free survival was 9.9 versus 4.2 months, intracranial response was 47.3 versus 20.0 percent, and median overall survival was 18.1 versus 12.0 months.
- Intracranial objective response 47.3 percent vs 20.0 percent.
- Median central nervous system progression-free survival 9.9 vs 4.2 months; median overall survival 18.1 vs 12.0 months.
This analysis is the evidence base for treating active HER2-positive brain metastases with a systemic regimen, sometimes deferring radiotherapy, and for tucatinib's brain-specific labelling.
- Exploratory subgroup analysis, though prespecified.
- Local therapy was permitted at isolated brain progression, which complicates interpretation.
Similar pages
not linked directly; found by shared links- Key paperHER2CLIMB: tucatinib with trastuzumab and capecitabine for HER2-positive metastatic breast cancer, including brain metastases
Shares HER2CLIMB, HER2-positive breast cancer with brain metastases, Tucatinib, Capecitabine.
- PairingTucatinib + trastuzumab + capecitabine for brain metastases
Shares HER2CLIMB, HER2-positive breast cancer with brain metastases, Tucatinib, Trastuzumab.
- TrialHER2CLIMB-05
Shares HER2-positive breast cancer with brain metastases, Tucatinib, Trastuzumab.
- TrialA Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)
Shares Tucatinib, Capecitabine, Trastuzumab.
- IdeaSystemic-first management of HER2-positive brain metastases
Shares HER2CLIMB, HER2-positive breast cancer with brain metastases, Tucatinib.
- TrialHER2CLIMB-02
Shares HER2-positive breast cancer with brain metastases, Tucatinib.
- PersonNancy U. Lin
- TrialTucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Shares Tucatinib, Capecitabine, Trastuzumab.